If enacted, this bill would specifically affect the regulatory framework surrounding orphan drugs, which are critical for treating rare diseases. By extending exclusivity periods, it aims to bolster the financial incentives for pharmaceutical companies to invest in the development of these drugs. Proponents argue that the policy shift is vital to encourage continued research and development efforts in the context of the ongoing healthcare challenges exacerbated by COVID-19.
Summary
House Bill 1805, referred to as 'Leo's Law', aims to mitigate the effects of the COVID-19 pandemic on incentives for developing orphan drugs under the Federal Food, Drug, and Cosmetic Act. The bill proposes that key exclusivity periods for certain orphan drugs are to be extended by an additional 180 days, provided these periods have not yet expired. This extension is intended to support the pharmaceutical industry's ability to bring rare disease medications to market despite challenges posed by the pandemic.
Contention
While the intent of HB1805 is widely recognized as supportive of public health goals, there might be debates around the implications of extending exclusivity periods. Critics may caution that extending patent protections could hinder access to these medications by delaying the entry of generics and biosimilars into the market. There is concern that it may lead to higher drug costs, making these essential treatments less accessible for those who need them most. Balancing the interests of drug developers with the need for affordable medicines will likely be a point of contention during discussions related to this legislation.
Residential Substance Use Disorder Treatment Act of 2023 This bill revises and reauthorizes through FY2027 grants for residential substance use disorder treatment programs at state and local correctional and detention facilities. Among the revisions, the bill replaces statutory references to substance abuse with substance use disorder, specifies that the term residential substance use disorder treatment program includes a medication-assisted treatment program, requires the chief medical officer or other staff overseeing a program to complete training on the science of addiction and the latest research and clinical guidance on treating substance use disorders in criminal justice settings, and allows people who are awaiting trial or in pretrial detention to participate in the programs.
Support And Value Expectant Moms and Babies Act of 2023 or the SAVE Moms and Babies Act of 2023 This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved. Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner. The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient. The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)